Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment;Asthmakontrolle mit dem salmeterol/fluticason kombinationsdiskus in hoher und mittlerer dosis im vergleich zur standardtherapie

Pneumologie

Volumn 59, Issue 3, 2005, Pages 167-173

  Molitor, S ^a   Liefring, E ^b   Traytmann, Marion ^c  

^a Allergo Medic Klinisches Institut   (Germany)

^b Arztin Lungen /Bronchialheilkunde   (Germany)

^c GLAXOSMITHKLINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; DISKUS; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST; SALMETEROL; STEROID; THEOPHYLLINE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TITRIMETRY; COMPARATIVE STUDY; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; REPRODUCIBILITY;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS;

EID: 17144374047     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830175     Document Type: Article

References (16)

1. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60: 1207-1233
2. Wettengel R, Steinkamp G. Rationale Kombination für die Asthmatherapie - Salmeterol und Fluticason in einem Präparat. Pneumologie 1999; 53: 426-432
3. Wettengel R, Berdel D, Hofmann D et al. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 1998; 52: 591-601
4. Quanjer PH. Standardized lung function testing. Report Working Party "Standardization of Lung Function Tests", European Community for Coal and Steel. Bull Europ Physiopathol Respir 1983; 19: 1-95
5. National Heart Lung and Blood Institute, WHO. Global strategy for asthma management and prevention NHLBI/WHO Workshop. 95-3659, 40-43, 1995. National Institutes of Health. National asthma education and prevention program. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Publication no. 97-4051A. Bethesda, MD: National Heart, Lung, and Blood Institute, 1997: 1-50., National Institutes of Health. www.ginasthma.com
6. National Heart Lung and Blood Institute, WHO. Global strategy for asthma management and prevention NHLBI/WHO Workshop. 95-3659, 40-43, 1995. National Institutes of Health. National asthma education and prevention program. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Publication no. 97-4051A. Bethesda, MD: National Heart, Lung, and Blood Institute, 1997: 1-50., National Institutes of Health. www.ginasthma.com
7. Bateman ED, Boushey HA, Bousquet J et al. Achieving and maintaining guideline defined asthma control with salmeterol/fluticasone propionate versus fluticasone propionate alone: the results of the GOAL study [Poster J89]. American Journal of Respiratory and Critical Care Medicine 2004; 170: 836-844
8. Condemi JJ, Goldstein S, Kalberg C et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999; 82: 383-389
9. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma [see comments]. Ann Allergy Asthma Immunol 1999; 82: 257-265
10. Noord JA van, Schreurs AJ, Mol SJ et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54: 207-212
11. Bergmann KC, Lindemann L, Braun R et al. Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004; 134: 50-58
12. Ind PW, dal Negro R, Colman NC et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003; 97: 555-562
13. Busse W, Koenig SM, Oppenheimer J et al. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. J Allergy Clin Immunol 2003; 111: 57-65
14. Jarjour N, Laviolette M, Moore WC et al. Control of Airway Inflammation and Remodeling is Preserved during a 60% Reduction in ICS Dose with Fluticasone Propionate/Salmeterol (FSC): Comparison with Higher Dose Fluticasone Propionate (FP) Alone [B62] [Poster: K81]. American Journal of Respiratory and Critical Care Medicine 2004; 169 (7): A451
15. Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002; 109: 929-935
16. Oppenheimer J, Stauffer J, Waitkus-Edwards K et al. "Stepping Down" from Fluticasone Propionate/Salmeterol 100/50 meg Diskus® Results in Loss of Asthma Control [A37] [Poster: J94]. American Journal of Respiratory and Critical Care Medicine 2004; 169 (7): A88